Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
ConditionRelapsed Ovarian Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJin Li
About this trial
This study is a Phase II single-arm, open label, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma .
Eligibility criteria
Qualifiers
The patient voluntarily joined the study and signed the informed consent.
Age 18-75 years old.
Participant has histologically confirmed diagnosis of high-grade predominantly serous ovarian cancer, fallopian tube cancer, primary peritoneal cancer; Or moderately or poorly differentiated ovarian endometrioid adenocarcinoma.
Previously, after undergoing 2-3 lines of platinum containing chemotherapy, CR or PR was achieved, and the time from the penultimate platinum containing chemotherapy to PD was ≥ 6 months.
Disqualifiers
Previous (within 5 years) or concurrent with other uncured malignant tumors, except for cured skin basal cell carcinoma, thyroid cancer, cervical carcinoma in situ and breast cancer with no recurrence >3 years after radical surgery.
The subject has untreated central nervous system metastasis.
Inability to swallow pills normally, or gastrointestinal dysfunction, which may affect drug absorption according to the researchers.
Recent (within 3 months) occurrence of intestinal obstruction.
Trial design
Treatments tested in this trial
- Fluzoparib
- Apatinib
Treatment groups
54 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Jin Li
Lead sponsor
Fudan University
Sponsor institution
Source ClinicalTrials.gov